Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rudin

Showing results (311-320 of 524) with videos related to

Pageof 53
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2023
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLCIgor Odintsov, Maisam Makarem, Mizuki Nishino, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumabMichael Offin, Narek Shaverdian, Andreas Rimner, et al.
The Oncologist|May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumorsIan Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
Iscience|October 29, 2021
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancerRebecca Caeser, Christopher Hulton, Emily Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low ToxicityKathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsSiddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancerM Catherine Pietanza, Anya M Litvak, Anna M Varghese, et al.
Cancer Discovery|November 6, 2023
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung AdenocarcinomaZhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
Pageof 53

Showing results (311-320 of 524) with videos related to

Sort By:
Pageof 53
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2023
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLCIgor Odintsov, Maisam Makarem, Mizuki Nishino, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumabMichael Offin, Narek Shaverdian, Andreas Rimner, et al.
The Oncologist|May 11, 2025
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumorsIan Nykaza, Yonina R Murciano-Goroff, Antoine Desilets, et al.
Iscience|October 29, 2021
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancerRebecca Caeser, Christopher Hulton, Emily Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low ToxicityKathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsSiddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancerM Catherine Pietanza, Anya M Litvak, Anna M Varghese, et al.
Cancer Discovery|November 6, 2023
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung AdenocarcinomaZhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
Pageof 53